LEXX News and Press, Lexaria Bioscience Corp. From 05/01/24

Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug-delivery platforms, has entered into a warrant exercise agreement with an existing accredited investor to exercise in full existing warrants. Specifically, the agreement is comprised of the purchase of 2,917,032 shares of commo...

KELOWNA, BC / ACCESSWIRE / April 30, 2024 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces it has entered into a warrant exercise agreement with an existing accredited investor to exercise in full certain...

Lexaria, a global innovator in drug delivery platforms, has received approval for its GLP-1 human pilot study #2 by an independent third-party ethics review board GLP-1 drugs are utilized in the treatment of type 2 diabetes and obesity, a huge market, and are typically administered by painful a...

2024-04-17 10:00:55 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Short interest in S&P 500 health stocks rises, Moderna among m...

2024-04-16 12:38:35 ET More on Lexaria Bioscience Corp. Lexaria to test DehydraTECH GLP-1 product for weight loss, diabetes Lexaria slips despite FDA nod to test blood pressure drug Seeking Alpha’s Quant Rating on Lexaria Bioscience Corp. Historical ea...

Lexaria, a global innovator in drug delivery platforms, has added three new patents to its portfolio, bringing the total to 41 Two patents were awarded in the U.S., while the third was awarded in Japan, expiring in 2042 and 2041, respectively, if not extended Lexaria’s management plans...

(TheNewswire) Human Pilot Study #2 (GLP-1-H24-2) Approved Kelowna, British Columbia – TheNewswire – April 16, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”), a global innovator in drug d...

Lexaria Bioscience Corp. (NASDAQ: LEXX) , a global innovator in drug delivery platforms, recently announced $3.6 million in gross proceeds from its registered direct offering. “Most notably, Lexaria intends to use the net proceeds from this offering for research and development (‘R&...

Lexaria, a global innovator in drug delivery platforms, has announced the appointment of Nelson Cabatuan, CPA, as its new CFO Nelson will lend over 15 years of experience in corporate finance and operations, having worked in key organizations within the industry, and will play an integral role ...

2024-04-08 16:08:57 ET LEXARIA BIOSCIENCE MAKING BIG MOVES IN THE LUCRATIVE GLP-1 MARKET The history of scientific discovery is the history of happy accidents. Those serendipitous surprises which lead to ground-breaking discoveries that make even the most seasoned sc...